{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:35:05Z","timestamp":1790062505142,"version":"4.0.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T00:00:00Z","timestamp":1450656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s13311-015-0410-6","type":"journal-article","created":{"date-parts":[[2015,12,21]],"date-time":"2015-12-21T10:05:26Z","timestamp":1450692326000},"page":"147-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-2000","authenticated-orcid":false,"given":"Matteo","family":"Gastaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Thouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0410-6_bib1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nrneurol.2012.99","article-title":"Neuronal autoantigens\u2014pathogenesis, associated disorders and antibody testing","volume":"8","author":"Lancaster","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1474-4422(11)70096-5","article-title":"Autoantibodies associated with diseases of the CNS: new developments and future challenges","volume":"10","author":"Vincent","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1473-3099(10)70222-X","article-title":"Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study","volume":"10","author":"Granerod","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1007\/s13311-015-0410-6_bib4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ana.20614","article-title":"Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma","volume":"58","author":"Vitaliani","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/brain\/awq113","article-title":"N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ana.21756","article-title":"Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents","volume":"66","author":"Florance","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jpeds.2012.10.011","article-title":"Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients","volume":"162","author":"Armangue","year":"2013","journal-title":"J Pediatr"},{"key":"10.1007\/s13311-015-0410-6_bib13","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1212\/WNL.0b013e3182a4a49c","article-title":"Late-onset anti-NMDA receptor encephalitis","volume":"81","author":"Titulaer","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-015-0410-6_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jnnp-2011-300411","article-title":"Cognitive deficits following anti-NMDA receptor encephalitis","volume":"83","author":"Finke","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0410-6_bib16","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0410-6_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/brain\/awu310","article-title":"Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice","volume":"138","author":"Planagum\u00e0","year":"2015","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib18","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/brain\/awv257","article-title":"Epileptogenic effects of NMDAR-antibodies in a passive transfer mouse model","volume":"138","author":"Wright","year":"2015","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0000000000000126","article-title":"Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis","volume":"82","author":"Viaccoz","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/archdischild-2014-306795","article-title":"N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children","volume":"100","author":"Wright","year":"2015","journal-title":"Arch Dis Child"},{"key":"10.1007\/s13311-015-0410-6_bib21","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1007\/s00415-011-5982-4","article-title":"Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies","volume":"258","author":"Alexopoulos","year":"2011","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp.2007.136473","article-title":"Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis","volume":"79","author":"Seki","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0410-6_bib23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jca.20311","article-title":"Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis","volume":"26","author":"Pham","year":"2011","journal-title":"J Clin Apher"},{"key":"10.1007\/s13311-015-0410-6_bib24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/dmcn.12411","article-title":"Does early treatment improve outcomes in N-methyl-D-aspartate receptor encephalitis?","volume":"56","author":"Byrne","year":"2014","journal-title":"Develop Med Child Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejpn.2011.07.005","article-title":"Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with cyclophosphamide: the need for early aggressive immunotherapy in tumour negative paediatric patients","volume":"16","author":"Kashyape","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ejpn.2012.03.004","article-title":"Anti-NMDA receptor encephalitis: the importance of early diagnosis and aggressive immunotherapy in tumor negative pediatric patients","volume":"16","author":"Kurian","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00401-009-0582-4","article-title":"Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma","volume":"118","author":"T\u00fcz\u00fcn","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-015-0410-6_bib28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e318228c136","article-title":"Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis","volume":"77","author":"Martinez-Hernandez","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/WNL.0b013e31822cfc6b","article-title":"Analysis of relapses in anti-NMDAR encephalitis","volume":"77","author":"Gabilondo","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib30","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jneuroim.2013.09.017","article-title":"Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts","volume":"265","author":"Hachiya","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0410-6_bib32","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0883073813520497","article-title":"Anti-N-methyl-d-aspartate (Anti-NMDA) receptor encephalitis: rapid and sustained clinical improvement with steroid therapy starting in the late phase","volume":"29","author":"Turkdogan","year":"2014","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib33","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1212\/01.wnl.0000336648.43562.59","article-title":"Response of anti-nmda receptor encephalitis without tumor to immunotherapy including rituximab","volume":"71","author":"Ishiura","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jca.21212","article-title":"Therapeutic plasma exchange in anti-N-methyl-D-aspartate-receptor (anti-NMDA-R) encephalitis associated with benign ovarian teratoma","volume":"27","author":"Batra","year":"2012","journal-title":"J Clin Apher"},{"key":"10.1007\/s13311-015-0410-6_bib35","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1212\/WNL.0b013e31820c34de","article-title":"Prolonged follow-up and CSF antibody titers in a patient with anti-NMDA receptor encephalitis","volume":"76","author":"Frechette","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib36","first-page":"1566","article-title":"Anti-N-methyl-D-aspartate receptor encephalitis: a patient with refractory illness after 25 months of intensive immunotherapy","volume":"70","author":"Thomas","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib37","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/dmcn.12545","article-title":"Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children","volume":"57","author":"Tatencloux","year":"2015","journal-title":"Develop Med Child Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib38","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(13)70070-X","article-title":"Prevalence and treatment of anti-NMDA receptor encephalitis","volume":"12","author":"Liba","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.25626","article-title":"N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse","volume":"29","author":"Hacohen","year":"2014","journal-title":"Move Disord"},{"key":"10.1007\/s13311-015-0410-6_bib40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.25623","article-title":"Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor","volume":"29","author":"Mohammad","year":"2014","journal-title":"Move Disord"},{"key":"10.1007\/s13311-015-0410-6_bib41","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1212\/WNL.0000000000002125","article-title":"Autoimmune post-herpes simplex encephalitis of adults and teenagers","volume":"85","author":"Armangue","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/NP300666","article-title":"Clinical Neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-Daspartate receptor antibodies are part of the problem","volume":"32","author":"Hoftberger","year":"2013","journal-title":"Clin Neuropathol"},{"key":"10.1007\/s13311-015-0410-6_bib43","first-page":"219","article-title":"A syndrome of continous muscle-fibre activity","volume":"24","author":"Isaac","year":"1961","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0410-6_bib44","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ana.410380505","article-title":"Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves","volume":"38","author":"Shillito","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib45","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/brain\/124.12.2417","article-title":"Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels","volume":"124","author":"Liguori","year":"2001","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ana.23577","article-title":"Morvan syndrome: clinical and serological observations in 29 cases","volume":"72","author":"Irani","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib47","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","article-title":"Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series","volume":"9","author":"Lai","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib48","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/brain\/awq213","article-title":"Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib49","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamaneurol.2013.592","article-title":"Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping","volume":"70","author":"Klein","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib50","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00415-014-7588-0","article-title":"An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre","volume":"262","author":"Huda","year":"2015","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib51","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/jnnp-2013-305218","article-title":"Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre","volume":"85","author":"Paterson","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0410-6_bib52","doi-asserted-by":"crossref","unstructured":"Hacohen Y, Singh R, Rossi M, et al. Clinical relevance of voltage-gated potassium channel-complex antibodies in children. Neurology 2015 Aug 21 [Epub ahead of print].","DOI":"10.1212\/WNL.0000000000001922"},{"key":"10.1007\/s13311-015-0410-6_bib53","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/123.7.1481","article-title":"Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients","volume":"123","author":"Gultekin","year":"2000","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.1097","article-title":"Potassium channel antibodies in two patients with reversible limbic encephalitis","volume":"50","author":"Buckley","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib55","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00415-014-7408-6","article-title":"Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity","volume":"261","author":"Malter","year":"2014","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib56","doi-asserted-by":"crossref","unstructured":"Khan N, Jeffree M, C G, Macleod W, Al-Sarraj S. Histopathology of VGKC antibody-associated limbic encephalitis. Neurology 2009;72:1703-1705.","DOI":"10.1212\/WNL.0b013e3181a55eb3"},{"key":"10.1007\/s13311-015-0410-6_bib57","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/brain\/aws082","article-title":"Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis","volume":"135","author":"Bien","year":"2012","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1528-1167.2010.02756.x","article-title":"Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission","volume":"52","author":"Lalic","year":"2011","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-015-0410-6_bib59","doi-asserted-by":"crossref","first-page":"18161","DOI":"10.1523\/JNEUROSCI.3506-13.2013","article-title":"Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors","volume":"33","author":"Ohkawa","year":"2013","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0410-6_bib60","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.yebeh.2010.01.017","article-title":"Improvement of non-paraneoplastic voltage-gated potassium channel antibody-associated limbic encephalitis without immunosuppressive therapy","volume":"17","author":"Gast","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-015-0410-6_bib61","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1212\/01.WNL.0000122648.19196.02","article-title":"Potenitally reversible autoimmune limbic encephalitis with neuronal potassium channel antibody","volume":"62","author":"Thieben","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib62","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/awh077","article-title":"Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis","volume":"127","author":"Vincent","year":"2004","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib63","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.22297","article-title":"Investigations of CASPR2, an autoantigen of encephalitis and neuromyotonia","volume":"69","author":"Lancaster","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2013.10.005","article-title":"VGKC-complex\/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy","volume":"265","author":"Shin","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0410-6_bib65","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/jnnp.2009.178293","article-title":"An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis","volume":"81","author":"Wong","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0410-6_bib66","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/brain\/awt212","article-title":"Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype","volume":"136","author":"Irani","year":"2013","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib67","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jca.21233","article-title":"Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature","volume":"27","author":"Jaben","year":"2012","journal-title":"J Clin Apher"},{"key":"10.1007\/s13311-015-0410-6_bib68","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jamaneurol.2014.463","article-title":"Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy","volume":"71","author":"Irani","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib69","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/jnnp-2013-306724","article-title":"Persistent anterograde amnesia following limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex","volume":"85","author":"Butler","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-015-0410-6_bib70","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ana.22307","article-title":"Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis","volume":"69","author":"Irani","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib71","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1212\/WNL.0b013e3182152808","article-title":"Tonic seizures: a diagnostic clue of anti-lgi1 encephalitis?","volume":"76","author":"Andrade","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib72","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archneurol.2011.2985","article-title":"Autoimmune epilepsy: clinical characteristics and response to immunotherapy","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib73","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.23756","article-title":"Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels","volume":"73","author":"Boronat","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib74","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1212\/WNL.0000000000000372","article-title":"Progressive encephalomyelitis with rigidity and myoclonus","volume":"82","author":"Balint","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib75","doi-asserted-by":"crossref","unstructured":"W.O. T, Lennon VA, Komorowski L, et al. DPPX potassium channel antibody frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014;83:1797-1803.","DOI":"10.1212\/WNL.0000000000000991"},{"key":"10.1007\/s13311-015-0410-6_bib76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2009.09.004","article-title":"Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality?","volume":"287","author":"Blanc","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-015-0410-6_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jca.21342","article-title":"Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti-GAD antibody-related epilepsy: quantification of the antibody response","volume":"30","author":"Farooqi","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1007\/s13311-015-0410-6_bib78","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1684\/epd.2013.0607","article-title":"Acute amnesia and seizures in a young female","volume":"15","author":"Garcia Garcia","year":"2013","journal-title":"Epileptic Disord"},{"key":"10.1007\/s13311-015-0410-6_bib79","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2014.05.032","article-title":"Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase","volume":"343","author":"Markakis","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-015-0410-6_bib80","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.transci.2008.09.005","article-title":"Plasma exchange for anti GAD associated non paraneoplastic limbic encephalitis","volume":"39","author":"Mazzi","year":"2008","journal-title":"Transfus Apher Sci"},{"key":"10.1007\/s13311-015-0410-6_bib81","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/archneurol.2012.234","article-title":"Anti-glutamic acid decarboxylase limbic encephalitis without epilepsy evolving into dementia with cerebellar ataxia","volume":"69","author":"Mirabelli-Badenier","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib82","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00415-010-5476-9","article-title":"Treatment of anti-glutamic acid decarboxylase antibody-associated limbic encephalitis with mycophenolate mofetil","volume":"257","author":"Saidha","year":"2010","journal-title":"J Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib83","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/ene.12186","article-title":"Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis","volume":"20","author":"Frisch","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib84","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ana.21917","article-title":"Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis","volume":"67","author":"Malter","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib85","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/brain\/awn183","article-title":"Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association","volume":"131","author":"Saiz","year":"2008","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib86","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib87","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaneurol.2015.0749","article-title":"Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies","volume":"72","author":"Arino","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib88","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ana.21589","article-title":"AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location","volume":"65","author":"Lai","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib89","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1212\/WNL.0000000000001682","article-title":"Encephalitis and AMPA receptor antibodies Novel findings in a case series of 22 patients","volume":"84","author":"H\u00f6fteberger","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib90","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2014.02.011","article-title":"Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis","volume":"270","author":"Kim","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0410-6_bib91","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB receptor antibodies","volume":"81","author":"H\u00f6ftberger","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib92","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","article-title":"Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies","volume":"13","author":"Petit-Pedrol","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib93","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1212\/WNL.0000000000001326","article-title":"Antibodies to GABAA receptor A1 and G2 subunits","volume":"84","author":"Pettingill","year":"2015","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib94","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonzalez","year":"2014","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib95","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2014.3602","article-title":"Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated optic neuritis","volume":"72","author":"Martinez-Hernandez","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib96","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/epi.12528","article-title":"Investigation of neuronal autoantibodies in two different focal epilepsy syndromes","volume":"55","author":"Ekizoglu","year":"2014","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-015-0410-6_bib97","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib98","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/brain\/aws256","article-title":"Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders","volume":"135","author":"Dale","year":"2012","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0410-6_bib99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM200001063420104","article-title":"Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor","volume":"342","author":"Smitt","year":"2000","journal-title":"N Eng J Med"},{"key":"10.1007\/s13311-015-0410-6_bib100","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/archneurol.2010.51","article-title":"Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis","volume":"67","author":"Marignier","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib101","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1212\/WNL.0b013e3182364a44","article-title":"Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome","volume":"77","author":"Lancaster","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0410-6_bib102","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"21","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0410-6_bib103","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"Van Der Neut","year":"2007","journal-title":"Science"},{"key":"10.1007\/s13311-015-0410-6_bib104","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/ene.12758","article-title":"The expanding field of IgG4-mediated neurological autoimmune disorders","volume":"22","author":"Huijbers","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-015-0410-6_bib105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2222.2009.03207.x","article-title":"Immunoglobulin G4: an odd antibody","volume":"39","author":"Aalberse","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1007\/s13311-015-0410-6_bib106","doi-asserted-by":"crossref","unstructured":"Khosroshahi A, Bloch D, Deshpande V, JH. S. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010;62:1755-1762.","DOI":"10.1002\/art.27435"},{"key":"10.1007\/s13311-015-0410-6_bib107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-015-0410-6_bib108","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"key":"10.1007\/s13311-015-0410-6_bib109","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1177\/1352458514538111","article-title":"Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study","volume":"14","author":"Mancuso","year":"2014","journal-title":"Mult Scler"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0410-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0410-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0410-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:47:14Z","timestamp":1761806834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":109,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1878747923009467"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0410-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0410-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}